Investigating molecular profiles of ovarian cancer: An update on cancer stem cells

Journal of Cancer

Volumn 5, Issue 5, 2014, Pages 301-310

  Tomao, Federica ^a   Papa, Anselmo ^a   Martina, Strudel ^a   Rossi, Luigi ^a   Russo, Giuseppe Lo ^a   Panici, Pierluigi Benedetti ^a   Ciabatta, Francesca Romana ^a   Tomao, Silverio ^a  

^a POLICLINICO UMBERTO I   (Italy)

Author keywords

Cancer stem cells markers; Epithelial ovarian cancer; Ovarian cancer stem cells; Therapeutic targets; Tumor microenvironment

Indexed keywords

BETA SECRETASE INHIBITOR; CD133 ANTIGEN; CD24 ANTIGEN; CELL MARKER; ENTEROTOXIN; EPITHELIAL CELL ADHESION MOLECULE; ERIOCALYXIN B; HERMES ANTIGEN; HYALURONIC ACID; ISOFLAVAN DERIVATIVE; METFORMIN; NICLOSAMIDE; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG;

CANCER RESISTANCE; CANCER STEM CELL; CELL POPULATION; CLOSTRIDIUM PERFRINGENS; DRUG TARGETING; ENZYME ASSAY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; OVARY CANCER; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 84896912505     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.8610     Document Type: Review

References (125)

1. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011. CA Cancer J Clin. 2011;61:212-236.
2. Wang L, Mezencev R, Bowen NJ, et al. Isolation and characterization of stem-like cells from a human ovarian cancer cell line. Mol Cell Biochem. 2012;363:257-268.
3. Murdoch WJ, McDonnel AC. Roles of the ovarian surface epithelium in ovulation and carcinogenesis. Reproduction. 2002;123(6):743-750.
4. Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 1999, 91(17):1459-1467.
5. Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006;66:9339-9344.
6. Pardal R, Clarke MF, Morrison SJ: Applying the principles of stem-cell biology to cancer. Nat Rev Cancer. 2003;3:895-902.
7. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983-3988.
8. Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2007;64:7011-7021.
9. O'Brien CA, Pollett A, Gallinger S, et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445:106-110.
10. Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A. 2007;104:973-978.
11. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67:1030-1037.
12. Quintana E, Shackleton M, Sabel MS, et al. Efficient tumour formation by single human melanoma cells. Nature. 2008;456(7222):593-598.
13. Bonnet D, Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med.1997;3:730-737.
14. Tomao F, Papa A, Rossi L, et al. Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach. J Exp Clin Cancer Res. 2013;32:48. doi: 10.1186/1756-9966-32-48.
15. Collins AT, Berry PA, Hyde C, et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65:10946-10951.
16. Gao MQ, Choi YP, Kang S, et al. CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene. 2010;29:2672-2680.
17. Dalerba P, Clarke MF: Cancer stem cells and tumor metastasis: first steps into uncharted territory. Cell Stem Cell. 2007;1:241-242.
18. McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011;43(5):420-32.
19. Lim D, Oliva E. Precursors and pathogenesis of ovarian carcinoma. Pathology. 2013;45(3):229-42.
20. Auersperg N. The origin of ovarian carcinomas: a unifying hypothesis. Int J Gynecol Pathol. 2011;30(1):12-21.
21. Hill RP. Identifying cancer stem cells in solid tumors: case not proven. Cancer Res. 2006;66:1891-1895.
22. Vogel G: Stem cells. 'Stemness' genes still elusive. Science. 2003;302:371.
23. Zon LI: Intrinsic and extrinsic control of haematopoietic stem-cell self-renewal. Nature. 2008;453:306-313.
24. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105-111.
25. Liu S, Dontu G, Mantle ID, et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 2006;66(12):6063-6071.
26. Korkaya H, Paulson A, Charafe-Jauffret E, et al. Regulation of mammary stem/progenitor cells by PTEN/Akt/ß-catenin signaling. PLoS Biol. 2009;7(6):e1000121.
27. Itamochi H. Targeted therapies in epithelial ovarian cancer: molecular mechanisms of action. World Journal of Biological Chemistry. 2010;1(7):209-220.
28. Valent P, Bonnet D, De Maria R, et al. Cancer stem cell definitions and terminology: the devil is in the details. Nature Rev. Cancer. 2012;12:767-775.
29. Croker AK, Allan AL. Cancer stem cells: implications for the progression and treatment of metastatic disease. J Cell Mol Med. 2008;12(2):374-390.
30. Frosina G. DNA repair in normal and cancer stem cells, with special reference to the central nervous system. Curr Med Chem. 2009;16:854-866.
31. Charafe-Jauffret E, Ginestier C, Iovino F, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 2009;69(4):1302-1313.
32. Dontu G, Abdallah WM, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003;17(10):1253-1270.
33. Cabarcas SM, Mathews LA, Farrar WL. The cancer stem cell niche-there goes the neighborhood? Int. J. Cancer. 2011;129:2315-2327.
34. Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol.2011;29:591-599.
35. Mi JK, Young KS. Regulation of Ovarian Cancer Stem Cells or Tumor-Initiating Cells. Int J Mol Sci. 2013;14:6624-6648.
36. Chau WK, Ip CK, Mak AS, et al. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/beta-catenin-ATP-binding cassette G2 signaling. Oncogene. 2012;doi:10.1038/onc.2012.290.
37. Cao L, Shao M, Schilder J, et al. Tissue transglutaminase links TGF-beta, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer. Oncogene. 2012;31:2521-2534.
38. Nguyen LV, Vanner R, Dirks P, et al. Cancer stem cells: an evolving concept. Nature Rev. Cancer. 2012;12:133-143.
39. Mitra AK, Zillhardt M, Hua Y, et al. MicroRNAs Reprogram Normal Fibroblasts into Cancer-Associated Fibroblasts in Ovarian Cancer. Cancer Discov. 2012;2:1100-1108.
40. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144:646-674.
41. Tirino V, Desiderio V, Paino F, et al. Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. FASEB J. 2013;27(1):13-24.
42. Gaur P, Sceusi EL, Samuel S, et al. Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology. 2011;141(5):1728-37.
43. Goodell MA, Brose K, Paradis G, et al. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 1996;183:1797-1806.
44. Chiba T, Kita K, Zheng YW, et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology. 2006;44:240-251.
45. Seigel GM, Campbell LM, Narayan M, et al. Cancer stem cell characteristics in retinoblastoma. Mol Vis. 2005;11:729-737.
46. Haraguchi N, Utsunomiya T, Inoue H, et al. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells. 2006;24:506-513.
47. Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci. 2004;101:14228-14233.
48. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci U S A. 2006;103:11154-11159.
49. Landen CN Jr, Goodman B, Katre AA, et al. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther. 2010;9(12):3186-3199.
50. LatifiA, Luwor RB, Bilandzic M, et al. Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. PLoS One. 2012;7(10e): 46858. doi: 10.1371/journal.pone.0046858. Epub 2012 Oct 8.
51. Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood. 1997;90:5002-5012.
52. Spangrude GJ, Brooks DM. Mouse strain variability in the expression of the hematopoietic stem cell antigen Ly-6A/E by bone marrow cells. Blood. 1993;82:3327-3332.
53. Moserle L, Indraccolo S, Ghisi M, et al. The side population of ovarian cancer cells is a primary target of IFN-alpha antitumor effects. Cancer Res. 2008;68:5658-5668.
54. Corbeil D, Röper K, Hellwig A, et al. The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem. 2000;275(8):5512-5520.
55. Ferrandina G, Bonanno G, Pierelli L, et al. Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer. 2008;18:506-514.
56. Zhang J, Guo X, Chang DY, et al. CD133 expression associated with poor prognosis in ovarian cancer. Mod Pathol. 2012;25:456-464.
57. Baba T, Convery PA, Matsumura N, et al. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene. 2009;28(2):209-218.
58. Curley MD, Therrien VA, Cummings CL, et al. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells. 2009;27(12):2875-83.
59. Heider KH, Kuthan H, Stehle G, et al. CD44v6: a target for antibody-based cancer therapy. Cancer Immunol Immunother. 2004;53:567-579.
60. Misra S, Hascall VC, Berger FG, et al. Hyaluronan, CD44, and cyclooxygenase-2 in colon cancer. Connect Tissue Res. 2008;49(3):219-224.
61. Misra S, Toole BP, Ghatak S. Hyaluronan constitutively regulates activation of multiplereceptor tyrosine kinases in epithelial and carcinoma cells. J Biol Chem. 2006;281(46):34936-34941.
62. Alvero AB, Chen R, Fu HH, et al. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle. 2009;8:158-166.
63. Meng E, Long B, Sullivan P, et al. CD44+/CD24-ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival. Clin Exp Metastasis. 2012;:18.
64. Bapat SA, Mali AM, Koppikar CB, et al. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res. 2005;65:3025-3029.
65. Chen J, Wang J, Chen D, et al. Evaluation of characteristics of CD44 + CD117+ ovarian cancer stem cells in three dimensional basement membrane extract scaffold versus two dimensional monocultures. BMC Cell Biol. 2013;14:7.
66. Wei X, Dombkowski D, Meirelles K, et al. Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics. Proc Natl Acad Sci USA. 2010;107(44):18874-9.
67. Zhang S, Balch C, Chan MW, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008;68:4311-4320.
68. Alvero AB, Chen R, Fu HH, et al. Molecular phenotyping of human ovarian cancer stem cells unravel the mechanisms for repair and chemo-resistance. Cell Cycle. 2009;8(Suppl. 1):158-166.
69. Kristiansen G, Sammar M, Altevogt P. Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol. 2004;35(3):255-262.
70. Surowiak P, Materna V, Kaplenko I, et al. Unfavorable prognostic value of CD24 expression in sections from primary and relapsed ovarian cancer tissue. International Journal of Gynecological Cancer. 2006;16(2):515-521.
71. Choi YL, Kim SH, Shin YK, et al. Cytoplasmic CD24 expression in advanced ovarian serous borderline tumors. Gynecologic Oncology. 2005;97(2):379-386.
72. Gao MQ, Choi YP, Kang S, et al. CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene. 2010;29(18):2672-2680.
73. Luo L, Zeng J, Liang B, et al. Ovarian cancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome. Exp Mol Pathol. 2011;91:596-602.
74. Raspollini MR, Amunni G, Villanucci A, et al. c-KIT expression and correlation with chemotherapy resistance in ovarian carcinoma: an immunocytochemical study. Ann Oncol. 2004;15(4):594-597.
75. Imrich S, Hachmeister M, Gires O. EpCAM and its potential role in tumor-initiating cells. Cell Adh Migr. 2012;6:30-38.
76. Bellone S, Siegel ER, Cocco E, et al. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapyresistant epithelial ovarian cancer: Implications for epithelial cell adhesion molecule-specific immunotherapy. Int J Gynecol Cancer. 2009;19:860-866.
77. Yamashita T, Ji J, Budhu A, et al. EpCAM-positive hepatocellular carcinoma cells are tumor initiating cells with stem/progenitor cell features. Gastroenterology. 2009;136:1012-1024.
78. Lawrenson K, Gayther SA. Ovarian cancer: a clinical challenge that needs some basic answers. PLoS Med 2009; 6:e25.
79. Tothill IE. Biosensors for cancer markers diagnosis. Semin Cell Dev Biol. 2009;20:55-62.
80. Liu P, Brown S, Goktug T, et al. Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells. Br J of Cancer.2012;107:1488-1497.
81. Croker AK, Goodale D, Chu J, et al. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med. 2009;13:2236-2252.
82. Silva IA, Bai S, McLean K, et al. Aldehyde dehydrogenase and CD133 define angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res. 2011;71:3991-4001.
83. Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1:555-567.
84. García Campelo MRACG, Aparicio Gallego G, Grande Pulido E, et al. Stem cell and lung cancer development: Blaming the Wnt, Hh and Notch signalling pathway. Clin Transl Oncol. 2011;13:77-83.
85. Rask K, Nilsson A, Brannstrom M, et al. Wnt-signalling pathway in ovarian epithelial tumours: Increased expression of beta-catenin and GSK3beta. Br J Cancer. 2003;89:1298-1304.
86. Morris RJ, Liu Y, Marles L, et al. Capturing and profiling adult hair follicle stem cells. Nat Biotechnol. 2004;22:411-417.
87. McClanahan T, Koseoglu S, Smith K, et al. Identification of overexpression of orphan G protein-coupled receptor GPR49 in human colon and ovarian primary tumors. Cancer Biol Ther. 2006;5:419-426.
88. Colomiere M, Ward AC, Riley C, et al. Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br J Cancer. 2009;100:134-144.
89. Steg AD, Katre AA, Goodman B, et al. Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer. Clin Cancer Res. 2011;17:5674-5685.
90. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105-111.
91. Tomao F, Papa A, Rossi L, et al. Current status of bevacizumab in advanced ovarian cancer. Onco Targets Ther. 2013;6:889-99. doi: 10.2147/OTT.S46301.
92. Ishii H, Iwatsuki M, Ieta K, et al. Cancer stem cells and chemoradiation resistance. Cancer Sci. 2008;99:1871-1877.
93. Gimenez-Bonafe P, Tortosa A, Perez-Tomas R. Overcoming drug resistance by enhancing apoptosis of tumor cells. Curr Cancer Drug Targets. 2009;9:320-340.
94. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. 2006;355:1253-1261.
95. Dean M. ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia. 2009;14:3-9.
96. Donnenberg VS, Meyer EM, Donnenberg AD. Measurement of multiple drug resistance transporter activity in putative cancer stem/progenitor cells. Methods Mol Biol. 2009;568:261-279.
97. Anderson ME. Glutathione: an overview of biosynthesis and modulation. Chem Biol Interact. 1998;111-112:1-14.
98. Backos DS, Franklin CC, et al. The role of glutathione in brain tumor drug resistance. Biochem Pharmacol. 2012;83(8):1005-1012.
99. Wu WJ, Zhang Y, Zeng ZL, et al. ß-phenylethyl isothiocyanate reverses platinum resistance by a GSH-dependent mechanism in cancer cells with epithelial-mesenchymal transition phenotype. Biochem Pharmacol. 2013;85(4):486-96.
100. Kusumbe AP, Bapat SA. Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. Cancer Res. 2009;69:9245-9253.
101. Peinado H, Portillo F, Cano A. Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol. 2004;48:365-375.
102. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9:265-273.
103. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea-a paradigm shift. Cancer Res. 2006;66:1883-1890.
104. Sell S, Pierce GB. Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers. Lab Invest. 1994;70:6-22.
105. Yo YT, Lin YW, Wang YC, et al. Growth inhibition of ovarian tumor-initiating cells by niclosamide. Mol. Cancer Ther. 2012;11:1703-1712.
106. Alvero AB, Montagna MK, Holmberg JC, et al. Targeting the mitochondria activates two independent cell death pathways in ovarian cancer stem cells. Am J Reprod Immunol. 2011;65:438-447.
107. Leizer AL, Alvero AB, Fu HH, et al. Regulation of inflammation by the NF-kappaB pathway in ovarian cancer stem cells. Mol Cancer Ther. 2011;10:1385-1393.
108. Shank JJ, Yang K., Ghannam J, et al. Metformin targets ovarian cancer stem cells in vitro and in vivo. Gynecol Oncol 2012;127:390-397.
109. Slomiany MG; Dai L, Tolliver LB, et al. Inhibition of Functional Hyaluronan-CD44 Interactions in CD133-positive Primary Human Ovarian Carcinoma Cells by Small Hyaluronan Oligosaccharides. Clin Cancer Res. 2009;15:7593-7601.
110. Casagrande F, Cocco E, Bellone S, et al. Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of Clostridium perfringens enterotoxin. Cancer. 2011;117:5519-5528.
111. McAuliffe SM, Morgan SL, Wyant GA, et al. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad SciUSA. 2012;109 (E): 2939-2948.
112. Jin L., Hope KJ., Zhai Q., et al. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nature Med. 2006;12:1167-1174.
113. Vici P, Sergi D, Pizzuti L, et al. Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients. J Exp Clin Cancer Res. 2013;32(1):49
114. Van Rhenen A, van Dongen GAMS, Kelder A, et al. The novel AML stem cell associated antigen CLL1 aids in discrimination between normal and leukemic stem cells. Blood. 2007;110:2659-2666.
115. Jin L, Lee EM, Ramshaw HS, et al. Monoclonal antibody-mediated targeting of CD123, IL3 receptor a chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell. 2009;5:31-42.
116. Jδrεs M, Johnels P, Hansen N, et al. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL1 receptor accessory protein. Proc Natl Acad Sci USA 2010;107:16280-16285.
117. Tomao F, Panici PB, Frati L, et al. Emerging role of pemetrexed in ovarian cancer. Expert Rev Anticancer Ther. 2009;9(12):1727-35. doi: 10.1586/era.09.141.
118. Tomao F, Papa A, Rossi L, et al. Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer. Expert Opin Investig Drugs. 2014;23(1):37-53. doi: 10.1517/13543784.2013.839657.
119. Korkaya H, Wicha MS. Selective targeting of cancer stem cells: a new concept in cancer therapeutics. BioDrugs 2007;21:299-310.
120. Tu LC, Foltz G, Lin E, et al. Targeting stem cells-clinical implications for cancer therapy. Curr Stem Cell Res Ther. 2009;4:147-153.
121. Gupta PB, Onder TT, Jiang G, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009;138:645-659.
122. Curtin JC, Lorenzi MV. Drug discovery approaches to target Wnt signaling in cancer stem cells. Oncotarget. 2010;1:563-577.
123. Tomao F, Tomao S, Panici PB. Improvement in progression-free survival in OCEANS bevacizumab arm: a critical point of view. J Clin Oncol. 2013;31(1):166-7. doi: 10.1200/JCO.2012.44.6237.
124. Martelli AM, Evangelisti C, Follo YM, et al. Targeting the phosphatidylinositol 3kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cells. Curr Med Chem. 2011;18:2715-2726.
125. Takebe N, Harris PJ, Warren RQ, et al. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nature Rev Clin Oncol. 2011;8:97-106.